Advertisement
Advertisement
GILD
Gilead Sciences Inc
133.21
USDSponsored
+2.35
+1.80%
Aug 07, 15:59 UTC -4
Closed
After-Market
133.19
-0.02
-0.01%
GILD Earnings Reports
Positive Surprise Ratio
GILD beat 27 of 42 last estimates.
64%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$7.93B
/$2.26
Implied change from Q2 26 (Revenue/ EPS)
+1.65%
/-133.48%
Implied change from Q3 25 (Revenue/ EPS)
+2.09%
/-8.50%
Gilead Sciences Inc earnings per share and revenue
On Aug 04, 2026, GILD reported earnings of -6.75 USD per share (EPS) for Q2 26, beating the estimate of -7.37 USD, resulting in a 8.53% surprise. Revenue reached 7.80 billion, compared to an expected 7.55 billion, with a 3.38% difference. The market reacted with a -2.58% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 2.26 USD, with revenue projected to reach 7.93 billion USD, implying an decrease of -133.48% EPS, and increase of 1.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Xenon Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.16
Actual
-$1.11
Surprise
+4.36%
Edgewise Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.53
Surprise
-10.55%
Zai Lab Limited - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.46
Surprise
-599.09%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
FAQ
What were Gilead Sciences Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Gilead Sciences Inc reported EPS of -$6.75, beating estimates by 8.53%, and revenue of $7.80B, 3.38% above expectations.
How did the market react to Gilead Sciences Inc's Q2 2026 earnings?
The stock price moved down -2.58%, changed from $135.25 before the earnings release to $131.76 the day after.
When is Gilead Sciences Inc expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Gilead Sciences Inc's next earnings report?
Based on 10
analysts, Gilead Sciences Inc is expected to report EPS of $2.26 and revenue of $7.93B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement